Prescient Therapeutics Limited (AU:PTX) has released an update.
Prescient Therapeutics Limited’s 2024 Annual General Meeting saw the approval of key resolutions, including the election of Dr. Gavin Shepherd and Dr. James Campbell as directors, and the issuance of options to Dr. Shepherd. However, the proposal for a 10% placement facility was not carried, showcasing a significant shareholder dissent.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
